• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Prothena Corporation plc - Ordinary Shares (NQ:PRTA)

9.190 +0.140 (+1.55%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Prothena Corporation plc - Ordinary Shares

< Previous 1 2 3 Next >
News headline image
Prothena Announces Board of Directors Update
December 12, 2025
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025
November 19, 2025
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA
November 11, 2025
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Reports Third Quarter 2025 Financial Results and Business Highlights
November 06, 2025
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena to Report Third Quarter 2025 Financial Results on November 6
October 30, 2025
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease
October 01, 2025
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference
August 28, 2025
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program
August 27, 2025
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy
August 06, 2025
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Reports Second Quarter 2025 Financial Results and Business Highlights
August 04, 2025
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena to Report Second Quarter 2025 Financial Results on August 4
July 28, 2025
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Announces Corporate Restructuring
June 18, 2025
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease
June 16, 2025
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint
May 23, 2025
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Reports First Quarter 2025 Financial Results and Business Highlights
May 08, 2025
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena to Report First Quarter 2025 Financial Results on May 8
May 01, 2025
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights
February 20, 2025
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
February 13, 2025
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Announces Board of Directors Update
December 30, 2024
From Prothena Corporation plc
Via Business Wire
News headline image
Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease
December 19, 2024
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Reports Third Quarter 2024 Financial Results and Business Highlights
November 12, 2024
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena to Report Third Quarter 2024 Financial Results on November 12
November 05, 2024
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Announces Leadership Team Updates
September 27, 2024
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena to Participate in Upcoming Healthcare Conferences
August 29, 2024
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Reports Second Quarter 2024 Financial Results and Business Highlights
August 08, 2024
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena to Report Second Quarter 2024 Financial Results on August 8
August 01, 2024
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration
May 28, 2024
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Reports First Quarter 2024 Financial Results and Business Highlights
May 08, 2024
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena to Report First Quarter 2024 Financial Results on May 8
May 01, 2024
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
April 15, 2024
From Prothena Corporation plc
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap